226 related articles for article (PubMed ID: 25783510)
21. Ectopic ACTH-producing tumors of the chest and octreotide scintigraphy.
Filosso PL; Rena O; Ruffini E; Oliaro A
Eur J Cardiothorac Surg; 2002 Jun; 21(6):1126; author reply 1126-7. PubMed ID: 12048099
[No Abstract] [Full Text] [Related]
22. Use of 111In-DTPA-octreotide scintigraphy in the diagnosis of neuroendocrine and non-neuroendocrine tumors of the lung. Preliminary results.
Oliaro A; Filosso PL; Bello M; Casadio C; Angusti T; Masaneo I; Maggi G; Bisi G
J Cardiovasc Surg (Torino); 1997 Jun; 38(3):313-5. PubMed ID: 9219485
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
24. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
25. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
26. 111Indium pentetreotide imaging in the evaluation of head and neck tumors.
Myssiorek D; Tronco G
Laryngoscope; 2005 Oct; 115(10):1707-16. PubMed ID: 16222183
[TBL] [Abstract][Full Text] [Related]
27. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
28. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
29. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
30. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
31. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
[TBL] [Abstract][Full Text] [Related]
32. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
33. Advances in radio-imaging of neuroendocrine tumors.
Vekemans MC; Urbain JL; Charkes D
Curr Opin Oncol; 1995 Jan; 7(1):63-7. PubMed ID: 7696365
[TBL] [Abstract][Full Text] [Related]
34. [Somatostatin receptor scintigraphy].
Rasmussen K; Nielsen JT; Rehling M
Ugeskr Laeger; 2005 Dec; 167(49):4647-50. PubMed ID: 16336855
[TBL] [Abstract][Full Text] [Related]
35. Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series.
Iravani A; Mitchell C; Akhurst T; Sandhu S; Hofman MS; Hicks RJ
Clin Genitourin Cancer; 2021 Aug; 19(4):e200-e205. PubMed ID: 33678552
[No Abstract] [Full Text] [Related]
36. Combined Indium-111 octreotide scintigraphy and low-dose computed tomography in localization of neuroendocrine tumors.
Kjaer A; Dreyer M
Clin Nucl Med; 2003 Jun; 28(6):506-8. PubMed ID: 12917538
[No Abstract] [Full Text] [Related]
37. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
38. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
[No Abstract] [Full Text] [Related]
39. Sandostatin labeled with 99mTc: in vitro stability, in vivo validity and comparison with 111In-DTPA-octreotide.
Kolan H; Li J; Thakur ML
Pept Res; 1996; 9(3):144-50. PubMed ID: 8875594
[TBL] [Abstract][Full Text] [Related]
40. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE
J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]